|Bid||84.65 x 1400|
|Ask||89.41 x 800|
|Day's range||86.13 - 88.32|
|52-week range||84.50 - 120.27|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||19.15|
|Earnings date||02 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||29 Dec 1995|
|1y target est||119.40|
Shares of biopharma Neurocrine Biosciences (NASDAQ: NBIX) were down 9.8% in Tuesday's late trading following a disappointing third-quarter report. For the three-month stretch ending in September, Neurocrine turned $296 million in revenue into an operating profit of $0.64 per share. On the basis of generally accepted accounting principles (GAAP), however, profits of only $0.23 per share left the market wanting more, and arguably concerned.
NBIX earnings call for the period ending September 30, 2021.
Neurocrine (NBIX) delivered earnings and revenue surprises of -54.90% and 0.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?